Early Prevention of Obesity: Tackling from Conception

By Melike Belenli Gümüş

October 16, 2024

A recent article discusses the potential for monitoring obesity from the earliest stages of development, including during the fetal period in the womb. This proactive approach highlights the importance of addressing obesity right from conception in order to achieve early prevention of obesity.

Early Prevention of Obesity

The article highlights research focused on the early prevention of obesity through a project named “eprObes” (Early Prevention of Obesity). This initiative aims to implement interventions that could significantly lower the risk of obesity later in life.

Factors Influencing Obesity

The study aims to identify and understand the various factors that contribute to obesity, starting from the pre-conception period and continuing through pregnancy and early childhood. These factors include genetic, environmental, and lifestyle influences that can affect the development of obesity in children.

Importance of Prenatal Care

The research emphasises the critical role of prenatal care in monitoring both the mother’s and the fetus’s health. Preventive measures during pregnancy could be key in reducing the incidence of obesity later in life.

Long-Term Health Implications

By addressing obesity at its earliest roots, the study aims to lower the risk of long-term health complications associated with obesity, such as metabolic syndrome, diabetes, and other related health issues.

Overall, the article indicates a shift towards a more proactive and preventive approach to managing obesity, starting at the earliest possible stage of human development. This new focus could lead to healthier outcomes for future generations.

Reference url

Recent Posts

NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection with SGLT2 Inhibitors

By João L. Carapinha

February 19, 2026

Type 2 Diabetes Guidelines Reshape Initial Treatment The latest Type 2 Diabetes Guidelines from NICE (National Institute for Health and Care Excellence), published on 18 February 2026 as an update to guideline NG28 ("Type 2 diabe...
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation
MFN Policy Effectiveness in Countering Freeloading Claims The MFN policy effectiveness is evident in the coalition letter dated February 12, 2026, which opposes codifying Most-Favored-Nation (MFN) prescription drug pricing b...
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implications for Alzheimer&...

By HEOR Staff Writer

February 18, 2026

Dutch Health Insurance Rejects Lecanemab Coverage Zorginstituut Nederland's advisory letter dated 13 February 2026 recommends against including lecanemab (Leqembi®) in the Dutch basic health insurance package, marking a key lecanema...